PHOTO
Dubai: Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, has appointed Ousama Al Haj as General Manager and Head of Human Pharma for Gulf area, effective June 1st, 2020. Drawing on more than 20 years’ experience in the multinational pharmaceutical industry and having proved himself as a transformational leader, Ousama joins Boehringer Ingelheim where he held various leadership positions in the Gulf and Levant countries, most recently as Country Director for UAE, Bahrain, Oman and Qatar.
“We warmly welcome Ousama to Boehringer Ingelheim and look forward to drawing on his wealth of experience to oversee operations across the UAE and wider Gulf area. This region plays a significant role in the global operations of our company, attributed to its growing population needs and investment in healthcare infrastructure. Our current focus places patients and innovation as the driving force behind all actions, thereby preparing us for the next wave of growth. We firmly believe Ousama will prove to be an invaluable asset to the team in this regard,” said Mohammed Al-Tawil, Country Managing Director and Head of Human Pharma META.
Ousama’s addition to the team comes at an opportune time for Boehringer Ingelheim Middle East, Turkey and Africa, as the division holds the recognition as being the third fastest growing pharmaceutical multinational in the Middle East, Turkey and Africa region. His efforts are expected to contribute to the continued strong performance and consistent growth of the firm within the market.
Since his onboarding, he has seamlessly and successfully managed cross-country teams through efficient utilization of digital capabilities. This has allowed for enhanced connection with stakeholders and further development of the team’s skillset through dedicated training courses. Ousama aims to carry on adapting operations to the ‘new normal’ and ensure continued commitment to patients and the healthcare industry during this time.
-Ends-
About Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com .
For more information, please contact:
Stephanie Tasrini
Account Director | Healthcare
Asda’a BCW
stephanie.tasrini@bcw-global.com
OR
Sara Shamel
Head of External Communications – META
Boehringer Ingelheim
sara.shamel@boehringer-ingelheim.com
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
